Skip navigation

BPGbio™ Introduces The Next Evolution in Prostate Health Diagnostics

BPGbio™ is proud to introduce pstateDx™, an AI-discovered prostate cancer protein biomarker diagnostic. The pstateDx™ test is a non-PSA based unique molecular diagnostic blood test that measures Filamin A, a key biological driver of prostate cancer. The test has demonstrated enhanced capability of providing a risk score to differentiate between Benign Prostatic Hyperplasia (BPH) and aggressive prostate cancer at the time of initial screening.

About Prostate Health

Benign Prostatic Hyperplasia (BPH) is a common condition that increases with age and generates a false positive signal for Prostate Cancer when utilizing Prostate Specific Antigen (PSA) as a diagnostic tool. It presents with symptoms very similar to those of Prostate Cancer; however, BPH is non-malignant.  Collectively, these symptoms known as LUTS (lower urinary tract symptoms) make the two conditions nearly indistinguishable on presentation.

BPH is a dominant condition in men at risk for Prostate Cancer that often leads to over recommendation of Prostate biopsies.

Being able to make the distinction between BPH and Prostate Cancer early in the diagnostic pipeline is a much needed evolution in Prostate Health diagnostics.


Current Prostate Health Diagnostic Landscape

There is a Lack of Specificity Without Invasive Biopsy

The available tools for diagnosing Prostate Cancer are limited in usefulness or are invasive with risk of complications revealing an unmet need for better Prostate Health diagnostics.

Current Standard of Care for diagnosis includes:

The Unmet Need in Prostate Health Diagnostics

There is a clear and defined unmet need for the development of molecular diagnostics that stratify men with Benign Prostatic Hyperplasia (BPH) from those that have Prostate Cancer to prevent unnecessary Prostate biopsies.

The pstateDx™ Diagnostic Test

Advantages include:

  • Non-PSA based blood test helps clinicians differentiate between aggressive prostate cancer and Benign Prostatic Hyperplasia (BPH)
  • Measures Filamin A, a key biological driver of prostate cancer
  • May reduce the number of biopsies in men with BPH
  • Effectively rules out aggressive prostate cancers

Benefits to Prostate Diagnosis & Care:

Avoiding costly and invasive biopsies

Reduced anxiety related to elevated PSA levels

Enhanced diagnostic and care at patient Primary Care Physician (PCP)

The pstateDx™ Competitive Advantage

The pstateDx™ test promises demonstrated clinical utility in stratification of Benign Prostate Cancer Hyperplasia (BPH) from Prostate Cancer; thus, leading to the reduction of false positives and, as a result, less need for prostate biopsies.

The pstateDx™ test addresses this unmet need with exceptionally competitive demonstrated accuracy using serum-based testing (non-PSA based test).

Download pstateDx Tear-sheet (PDF)

Poster AACR 2024 Diagnostic assessment of Filamin A (FLNA) as a serum biomarker for identification of benign prostatic hyperplasia vs aggressive prostate cancer in a prospective Mexican cohort

Poster AACR 2023 Serum Filamin A is a Prognostic Biomarker for Screening Benign Prostatic Hyperplasia vs Prostate Cancer in Caucasian and African American Men